Indication
PIK3CA Gene Mutation
4 clinical trials
5 products
3 drugs
Clinical trial
A Phase lb/ll, Open Label, Single Arm Study to Assess Efficacy and Safety of Alpelisib and Capecitabine in Patients With PIK3CA Mutant Metastatic Colorectal Cancer Who Failed Two Prior Standard ChemotherapiesStatus: Active (not recruiting), Estimated PCD: 2024-02-28
Product
Alpelisib plus CapecitabineClinical trial
Bile Acid and Lipid Metabolism in Patients With Drug-induced Acute Insulin ResistanceStatus: Recruiting, Estimated PCD: 2026-06-10
Product
Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitorClinical trial
A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)Status: Not yet recruiting, Estimated PCD: 2026-06-01
Drug
AlpelisibProduct
MirdametinibClinical trial
Genomically-Guided Treatment Trial in Brain MetastasesStatus: Recruiting, Estimated PCD: 2024-10-01
Product
AbemaciclibProduct
PaxalisibDrug
EntrectinibDrug
Adagrasib